Efficacy of Autologous Blood-Derived Therapies in Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Wounds: a compendium of clinical research and practice · 2026-07 · 38 (7)
DOI: 10.25270/wnds/25085 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Wounds: a compendium of clinical research and practice, 2026-07. Verfasst von Robert J Snyder und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medical Education, Cardiff University School of Medicine, Cardiff, Wales, UK; drwound@aol.com. Hauptthemen laut MEDLINE: Blood Transfusion, Autologous, Diabetic Foot, Platelet-Rich Fibrin, Platelet-Rich Plasma.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Background
Diabetic foot ulcers (DFUs) are a significant complication of diabetes, leading to high morbidity rate, amputation, and health care costs. Autologous blood-derived products, including autologous whole blood clot (AWBC), platelet-rich plasma, and platelet-rich fibrin, have emerged as promising treatments that leverage the body’s own healing mechanisms.
Objective
To evaluate the efficacy of autologous blood-derived products compared with standard-of-care (SOC) treatment in achieving complete healing of DFUs by 12 weeks.
Methods
A systematic review and meta-analysis of sources published through April 2025 was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PubMed, Embase, and the Cochrane Library were searched. Randomized controlled trials (RCTs) reporting complete healing at 12 weeks were included. Data were pooled using a random effects model to calculate odds ratio (OR) with 95% CI.
Results
Six RCTs with a total of 629 patients met the inclusion criteria. Autologous blood-derived products significantly improved the odds of complete healing at 12 weeks compared with SOC (pooled OR, 2.24; 95% CI, 1.47-3.41; P = .0045). Among these products, AWBC demonstrated the highest efficacy, and there was minimal indication of publication bias.
Conclusion
Autologous blood-derived products significantly improve healing outcomes in DFUs compared with SOC, supporting their clinical use. Further research should refine product preparation methods and treatment durations to maximize efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Medical Education, Cardiff University School of Medicine, Cardiff, Wales, UK; drwound@aol.com.
- UCLA Fielding School of Public Health, Los Angeles, CA.
Zitieren
APA
Snyder, R. J., & Lee, M. (2026). Efficacy of Autologous Blood-Derived Therapies in Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Wounds: a compendium of clinical research and practice, 38(7). https://doi.org/10.25270/wnds/25085
Vancouver
Snyder RJ, Lee M. Efficacy of Autologous Blood-Derived Therapies in Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Wounds: a compendium of clinical research and practice. 2026;38(7). doi:10.25270/wnds/25085
BibTeX
@article{Snyder2026,
author = {Snyder, Robert J and Lee, Martin},
title = {Efficacy of Autologous Blood-Derived Therapies in Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Wounds: a compendium of clinical research and practice},
year = {2026},
volume = {38},
number = {7},
doi = {10.25270/wnds/25085}
}
EUVIMED